TY - JOUR AU - Jackisch, C; Hegg, R; Stroyakovskiy, D TI - Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC): The HannaH phase III study JO - J Clin Oncol VL - 33 PY - 2015 SP - Abstr. 585 N1 - (Suppl.) ER -